Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma. Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically. In the non-comparative, randomized, phase 2 NeoTrio trial, we investigated whether targeted therapy could boost the proportion of patients achieving long-term recurrence-free survival with neoadjuvant immunotherapy in resectable stage III BRAF
No takes yet. Share an insight, caveat, or question.
Long et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: